Morgan Stanley Starts Biogen (BIIB) at Overweight
BIIB Hot Sheet
Rating Summary:15 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Morgan Stanley initiates coverage on Biogen (NASDAQ: BIIB) with a Overweight. PT $140.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $117.78 yesterday, with a 52 week range of $65.39-$123.23.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $117.78 yesterday, with a 52 week range of $65.39-$123.23.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Credit Suisse Starts Carrizo Oil & Gas (CRZO) at Neutral
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
Create E-mail Alert Related Categories
New CoverageRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
